Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectablesReportar como inadecuado

Glycemic control among patients in China with type 2 diabetes mellitus receiving oral drugs or injectables - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

BMC Public Health

, 13:602

Health policies, systems and management in high-income countries


BackgroundThe prevalence of type 2 diabetes mellitus T2DM is increasing rapidly among Chinese adults, and limited data are available on T2DM management and the status of glycemic control in China. We assessed the efficacy of oral antidiabetes drugs OADs, glucagon-like peptide-1 GLP-1 receptor agonists, and insulin for treatment of T2DM across multiple regions in China.

MethodsThis was a multicenter, cross-sectional survey of outpatients conducted in 606 hospitals across China. Data from all the patients were collected between April and June, 2011.

ResultsA total of 238,639 patients were included in the survey. Eligible patients were treated with either OADs alone n=157,212 65.88%, OADs plus insulin n=80,973 33.93%, or OADs plus GLP-1 receptor agonists n=454 0.19%. The OAD monotherapy, OAD + insulin, and OAD + GLP-1 receptor agonist groups had mean glycosylated hemoglobin HbA1c levels ±SD of 7.67% ±1.58%, 8.21% ±1.91%, and 7.80% ±1.76%, respectively. Among those three groups, 34.63%, 26.21%, and 36.12% met the goal of HbA1c <7.0%, respectively. Mean HbA1c and achievement of A1c <7.0% was related to the duration of T2DM.

ConclusionsLess than one third of the patients had achieved the goal of HbA1c <7.0%. Glycemic control decreased and insulin use increased with the duration of diabetes.

KeywordsChina GLP-1 receptor agonists HbA1c Insulin Oral antidiabetes drugs OADs Type 2 diabetes mellitus Abbreviations2hPPG2-hr postprandial plasma glucose

ADAAmerican Diabetes Association

BMIBody mass index

DBPDiastolic blood pressure

DPP-4Dipeptidyl peptidase-4

FPGFasting plasma glucose

GLP-1Glucagon-like peptide-1

GLP-1 RAGLP-1 receptor agonist

LDLLow-density lipoprotein

OADsOral antidiabetes drugs

PPGPostprandial plasma glucose

SBPSystolic blood pressure

SDStandard deviation

SMBGSelf-monitored blood glucose

T1DMtype 1 diabetes mellitus

T2DMtype 2 diabetes mellitus

UKPDSUK Prospective Diabetes Study.

Electronic supplementary materialThe online version of this article doi:10.1186-1471-2458-13-602 contains supplementary material, which is available to authorized users.

Download fulltext PDF

Autor: Li-Nong Ji - Ju-Ming Lu - Xiao-Hui Guo - Wen-Ying Yang - Jian-Ping Weng - Wei-Ping Jia - Da-Jin Zou - Zhi-Guang Zhou - De-


Documentos relacionados